September 1, 2024Open Access

Progressive Disease with Mixed Response After Immunotherapy in Non-Small Cell Lung Cancer

Puntos clave

Los puntos clave no están disponibles para este artículo en este momento.

Resumen

There exists a dearth of research concerning non-small cell lung cancer (NSCLC) patients experiencing overall progressive disease concomitant with shrinking lesions after immunotherapy. This is a special type of mixed response. We aim to evaluate the clinical characteristics and treatment options of these patients during immunotherapy.

Leer artículo completoexternamente

Preguntar a la IA

Me gusta

Guardar

Ver artículo completo

Cite This Study

Lv et al. (Sun,) studied this question.

synapsesocial.com/papers/68e59d88b6db643587537edd https://doi.org/https://doi.org/10.2147/jir.s477244

Also Consider

Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context:

1Hyperprogressors after Immunotherapy: Analysis of Genomic Alterations Associated with Accelerated Growth Rate2017 · 852 citations
2Correction to: “Metastatic non-small cell lung cancer: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up”2019 · 324 citations
3New response evaluation criteria in solid tumours: Revised RECIST guideline (version 1.1)2008 · 29,546 citations
4Cetuximab rechallenge in metastatic colorectal cancer patients: how to come away from acquired resistance?2012 · 213 citations
5Systemic Immune-Inflammation Index Predicts Prognosis of Patients after Curative Resection for Hepatocellular Carcinoma2014 · 2,366 citations

Preguntar a la IA

Me gusta

Guardar

Ver artículo completo